Home › Scleroderma › NCT06672822
Intralesional Injection of STS in Treatment of Calcinosis
An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy * Must be over 18 years of age * Participants must be competent to give informed consent * Participants must have radiographic evidence (xray or ultrasound) of calcinosis. * Participants must need symptomatic relief Exclusion Criteria: • Pregnant women will be excluded
About the study
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
What is being tested
- Sodium Thiosulfate (STS) (drug)
Sponsor: Robyn T. Domsic, MD, MPH · Participants: 20 · Started: Mar 17, 2025
Contact the study team
- Maureen M Laffoon, BS · Phone: 412-648-7874
Official record on ClinicalTrials.gov — NCT06672822
Locations in the U.S.
| Pennsylvania | UPMC Arthritis and Autoimmunity Center, Pittsburgh |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.